Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wrong direction
right direction
Outstanding Shares a/o Jun 14, 2017
4,983,223,237 (Verified by Transfer Agent)
http://www.otcmarkets.com/stock/MLCG/profile
MLCG really want become current!
MLCG — Notification of Late Filing
Published: Jun 15, 2017 Period End: Dez 31, 2016
http://www.otcmarkets.com/financialReportViewer?symbol=MLCG&id=174490
MLCG — Notification of Late Filing
Published: Jun 15, 2017 Period End: Mär 31, 2017
http://www.otcmarkets.com/financialReportViewer?symbol=MLCG&id=174491
? why CNBX is running ?
yeah, bring on massive DILUTION
Letter of Intent with DinoStar, Inc.
ML Capital Group, Inc. Lays Foundation for a Disruptive Acquisition Strategy
http://ih.advfn.com/p.php?pid=nmona&article=75004956&symbol=MLCG
"A Strategy that Disrupts Tourism's Ugly White Elephant...and Gives it a Unicorn!"
MIAMI, FL / ACCESSWIRE / June 14, 2017 / ML Capital Group, Inc. (OTC PINK: MLCG) has executed a Letter of Intent with DinoStar, Inc., (NV) to acquire certain assets, know-how and ongoing operations to further grow a specific business inside MLCG's travel & tourism vertical. MLCG will pay DinoStar $2,000,000.00 for the acquisition; the Definitive Agreement of which, MLCG and DinoStar will execute upon MLCG becoming current with OTCmarkets.com. This acquisition will not only dramatically expand MLCG's tourism business, it will fundamentally disrupt the travel and tourism sector.
This, among other burgeoning opportunities that are already manifesting on the Company's immediate horizon, has motivated MLCG to take steps to fortify its existing foundation. Specifically, the Company has increased its authorized capital structure and created several new classes of preferred shares. The latter allows the company to provide new Officer and Director compensation plans, as well as an attraction mechanism for new, outside capital investment. Par value remains unchanged at $0.00001. In addition, while the Company has previously expressed desire to change the Company's name and symbol, it has elected to maintain the ML Capital Group, Inc. name, based entirely on this and other pending acquisitions.
"This acquisition brings a highly disruptive business to our balance sheet that has the potential to do $3m in 2017, $7m+ in 2018 with fantastic margins." added CEO Kevin Bobryk. "The changes we have made, and continue to make, lay the foundation for a strategy that disrupts tourism's ugly white elephant of a business, and gives it a unicorn. Adding and integrating our existing components to this exciting acquisition is ground breaking."
Details of the acquisition will be included in the forthcoming quarterly disclosure filing, in the subsequent events section.
For Further Information:
Platinum Tours Maui and ML Capital Group politely and formally request that all inquiries, whether stock-related or travel be submitted to investor relations at info@mlcginc.com.
Staff at the tour company will not and are not able to answer any inquiry, stock-related or otherwise. You will be directed to the info@mlcginc.com email address for further information and direction. Investor relations directly interfaces with the company and any questions related to tourism or travel will be immediately directed to the appropriate staff in the tour company.
Safe Harbor:
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
ML Capital Group
Contact: Investor Relations
Email: info@mlcginc.com
+1-786-313-3206
SOURCE: ML Capital Group, Inc.
Sponsoring was June, 10th - today it`s time for DILUTION
fuc...g MLCG!
June 10th Southeast Cannabis Conference and Expo (SECCExpo) at the Greater Ft. Lauderdale / Broward County Convention Center
ML Capital Group Sponsors James Roswell Quinn's Keynote to Launch Veterans Rally at South East Cannabis Conference in Florida
Jun 08, 2017
http://www.otcmarkets.com/stock/MLCG/news/ML-Capital-Group-Sponsors-James-Roswell-Quinn--39-s-Keynote-to-Launch-Veterans-Rally-at-South-East-Cannabis-Conference-in-Florida?id=161536&b=y
Transgenomic Stockholders and Precipio Diagnostics Members Approve Merger
Jun 06, 2017
http://www.otcmarkets.com/stock/TBIO/news/Transgenomic-Stockholders-and-Precipio-Diagnostics-Members-Approve-Merger?id=161147&b=y
OTC Disclosure & News Service
-
Transgenomic, Inc. (OTCBB: TBIO) today announced that its stockholders have approved the merger with Precipio Diagnostics, LLC. Upon completion of the merger, the company expects to meet the requirements for its stock to be relisted on NASDAQ under the new symbol “PRPO.”
Over 90% of the votes cast by Transgenomic shareholders were in favor of the merger and the other various proposals that were put forth for consideration at yesterday’s special stockholder meeting. In addition, Precipio Diagnostics’ members approved the merger with over 95% of the outstanding membership interests voting in favor. Both companies are continuing to work to close the combined company’s $7 million private placement of preferred convertible securities, as well as a conversion of all outstanding secured debt into the combined company’s preferred convertible securities.
Upon completion of these remaining conditions, the merger will be consummated. Additionally, the conversion of secured debt and planned capital infusion are expected to provide the combined company with a clean balance sheet and sufficient capital to pursue its planned expansion.
Paul Kinnon, Transgenomic President and Chief Executive Officer, said “We are very pleased that the merger with Precipio has been approved by the stakeholders in both companies. We believe that the combination of our leading ICE COLD-PCR mutation detection technology and Precipio Diagnostics’ unique business model and expertise aimed at improving the diagnosis and treatment of cancer has major clinical and commercial potential.”
“We are delighted to have reached this stage and received the approval of both companies’ stockholders and members for the merger. We appreciate everyone’s patience as the companies went through this long and complex process, and now we are ready to get to work and focus together on building the new company,” said Ilan Danieli, Precipio Diagnostics founder and Chief Executive Officer. “We believe strongly that this is the beginning of increased value creation for our stockholders and new investors, as we join these two companies’ business models and teams, utilizing our network of expertise, and proprietary technologies to deliver an improved level of diagnostic accuracy to patients.”
Transgenomic’s ICE COLD-PCR (ICP) offers major advantages over current sequencing technologies. It delivers at least a 100-fold improvement in sensitivity compared to standard methodologies, allowing detection of both known and previously unknown genetic alterations in any exon of any gene using a single assay. It is robust, easy to use and easily implemented, requiring minimal disruption to established sequencing workflows. ICP technology is available as ICEme™ Kits that deliver up to a 500-fold increase in mutation detection compared to most current methods, with levels of detection routinely achievable down to 0.01%. This ultra-high sensitivity enables detection of low level mutations that allow accurate patient monitoring as well as stratification of cancer sub-populations. ICEme Kits work well with most patient samples, including tissue, blood, plasma, urine and other biofluids. The kits are simple to use and work with most of the genomic analytic platforms available in laboratories today. They are easily customizable for use with single mutations or in combination. The current menu includes approximate 20 clinically relevant, actionable mutations that are associated with important cancers. Additional mutations are being added on an ongoing basis.
ICE COLD-PCR was originally developed by the laboratory of Dr. Mike Makrigiorgos at the Dana-Farber Cancer Institute, which has exclusively licensed rights to the technology to Transgenomic.
About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in oncology and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR, which enables use of liquid biopsies for mutation detection. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
About Precipio Diagnostics
Precipio Diagnostics has built a platform to harness the intellect, expertise and technology developed within academia, delivering quality diagnostic information to physicians and patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, and its experience delivering quality service, Precipio Diagnostics offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, visit precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements,” which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets, expectations regarding new clients, projects and prospects, and ICP’s ability to accelerate the Company’s growth and generate revenue. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005639/en/
Copyright © 2017 Businesswire. All Rights Reserved
The planned effective date of the reverse split is 5:00 p.m. EDT on June 5, 2017.
http://www.businesswire.com/news/home/20170525006028/en/
After the reverse split, the number of shares outstanding will be reduced from approximately 26.8 million shares to approximately 0.9 million shares.
no - it is not out...
more than 5 days later, where is this 10-q???
05/12/2017
Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
http://ih.advfn.com/p.php?pid=nmona&article=74579829
...The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date.
mCig in article: Booming Cannabis Market Providing an Array of Opportunities for Growing Number of Industries
May 19, 2017
Twitter@ mciginc:
mCig in article: Booming Cannabis Market Providing an Array of Opportunities for Growing Number of Industrieshttps://t.co/0R4qD2bZne
— Bots, Inc. (@Bots_bz) May 19, 2017
...but where is the Orphan Drug Designation??
Dec 7, 2016
https://finance.yahoo.com/news/colombia-resources-inc-provides-joint-154010264.html
NEWC is pleased to provide an update of their new joint venture to apply for an orphan drug designation with the FDA for a cannabis based pharmaceutical product within the next few weeks.
via settings to my removed posts
https://investorshub.advfn.com/boards/myremovedposts.aspx
hope to see some filings the next few days...
http://www.otcmarkets.com/stock/NEWC/filings
...In January 2017, a CT scan revealed lumps on his lungs; he then started a treatment of Sannabis' Pure Cannabis Indica Extract applied rectally. His PSA in January 2017 was 3.83, in February his PSA dropped to .87 and a CT scan showed the lumps had disappeared. In March, his level declined even further to .07, and last week it dropped to 0.
For the official Sannabis report on the patient visit, https://drive.google.com/open?id=0BxSKP5j2FlseU1BIU1FmSHB3eG8
These results are very encouraging to New Colombia Resources...
https://finance.yahoo.com/news/colombia-resources-inc-reports-sannabis-123540034.html
New Colombia Resources Inc. Issues Letter to Shareholders
April 26, 2017
https://finance.yahoo.com/news/colombia-resources-inc-issues-letter-193249174.html
BARRANQUILLA, COLOMBIA--(Marketwired - Apr 26, 2017) - New Colombia Resources, Inc. ("the Company") ( OTC PINK : NEWC ), a Colombian natural resource company listed in the U.S., with premium metallurgical coal and medical marijuana assets, is pleased to issue this letter to shareholders.
Dear Shareholders:
New Colombia Resources would like to thank all of our shareholders that believe in the Company. It could not be a better time for New Colombia due to the geo political environment for both coal and medical marijuana, two of the hottest industries in the World. Metallurgical coal, our main asset, has seen a surge in prices to six year highs. Metallurgical coal was the best performing commodity in 2016 with a price gain of over 85% and the trend is continuing this year, on April 17, 2017 spot prices for met coal were over $ 314 per tonne. Our cost to get metallurgical to the ports in Colombia is under $ 60 per tonne.
We have two coal properties we're developing, a wholly owned concession contract ILE-09551 in Guaduas, and concession contract JC3-15231in Cucuta, which is a JV with MSG Mining Corp. Additionally, we're entering into operating agreements for 8-10 mines that are producing between 1000-4000 tonnes/month of coal each. We will ramp these to double their production to fill several orders that are being negotiated as well as an existing order announced earlier this year. We've asked the Buyer of that order for an extension on the first delivery and are awaiting their response. We'll be working with financial instruments to finance our coal activities backed by standby letters of credits from Buyers going forward.
On Monday, I had a meeting at the National Mining Agency (ANM) that provides us with coal buyers that contact the agency. Several of these contacts will be turning into contracts. The ANM has been very helpful and I greatly appreciate their collaboration. While at the ANM we were notified to accept the approval of coal Concession Contract OJ8-08091 for up to 288 hectares of coal granted on March 22, 2017, to see notice visit, https://www.anm.gov.co/sites/default/files/atencion_minero/estado_056_del_10_de_abril_de_2017.pdf
On November 11, 2013, we filed an 8K when we applied for this concession contract, visit https://www.sec.gov/Archives/edgar/data/772370/000107878213002185/f8k111213_8k.htm
The Guaduas Formation metallurgical coal seam has been exploited from Boyacá, north east of Guaduas for over 30 years. The formation forms in Guaduas, hence the name, this is a mega project that we will pioneer with several mining titles already granted and more to come. For an estimate of reserves or our first mining concession contract ILE-09551 visit, http://www.newcolombiaresources.com/assesment.php
In late March 2017, we began shipping thermal coal to Puerto Brisa to fill a 3000-10,000 tonne per month contract entered into by our subsidiary, Compania Minera San Jose Ltda. Coal is being sourced from third parties to fill this order. Approximately 15 truckloads were sent and paid for in the first 10 days until the Buyer had a problem with port capacity. Trucks were waiting up to 48 hours to offload causing shipping delays and additional stand by costs. Shipments were expected to begin last week but were again delayed due to the port issues. The Buyer has since reserved more space at the port and deliveries should commence this Friday. To see pictures of our first coal truck and port delivery click the following link, although to some these don't mean much, to me it documents the beginning of decades of coal shipments and millions of tonnes, https://drive.google.com/open?id=0BxSKP5j2FlseaDFxVHhtc1RxWlk
I've secured another port in Cienega on the Atlantic Coast with a 600,000 tonne coal yard and the ability to support 150,000 tonne ships. This port, next to Prodeco's Puerto Nuevo, has all of its environmental permits, 24-hour security, and a conveyor belt system to load coal onto mega freighters. They accept deliveries 24 hours a day and their capacity is available to us since it is mostly being used to import and distribute petroleum products that are sold to trucking companies, there are hundreds of trucks available to us at this port.
NEWC @ OTC Markets
http://www.otcmarkets.com/stock/NEWC/profile
DILUTION goes on - MLCG is death
$mcig posts best earnings ever... zero debt in the black https://t.co/wF7c6B8ekb
— Jason Spatafora (@WolfOfWeedST) May 15, 2017
Proxy Statement - Merger or Acquistion
5/12/2017
http://ih.advfn.com/p.php?pid=nmona&article=74580228
...will be filed on or before the fifth calendar day following the prescribed due date...
http://ih.advfn.com/p.php?pid=nmona&article=74579829&symbol=MYDX
R.I.P. NEWC
R.I.P. MLCG
http://www.otcmarkets.com/stock/MLCG/profile
Authorized Shares 7,000,000,000 a/o May 01, 2017
Outstanding Shares 4,758,223,237 a/o May 01, 2017
Precipio Renews its Exclusive Agreement with Yale School of Medicine for an Additional Five Years
http://ih.advfn.com/p.php?pid=nmona&article=74380464
New Haven, CT : April 20 th , 2017 – Precipio Diagnostics, a company harnessing the experience, knowledge and expertise of academic-level pathology to deliver diagnostic accuracy to physicians and patients worldwide, announced that it has signed an exclusive agreement with Yale School of Medicine for an additional five years, after concluding its initial five year term.
Under the renewed agreement, Yale will continue to provide Precipio with exclusive access to its world-class pathologists for their professional diagnostic interpretation of clinical cases serving Precipio’s customers.
“Patients are often unaware of the fact that oncologists rely on outside laboratories which determine the diagnosis. This diagnosis drives patients’ treatment plans, and industry sources estimate as many as 10-20% of these cases are misdiagnosed,” said Ilan Danieli, CEO of Precipio Diagnostics. “We find this unacceptable. Precipio’s vision is to eliminate the problem of misdiagnosis by harnessing academic expertise and making it available to physicians and their patients. Together with Yale, we have served over 3,000 individuals, building a significant amount of data that clearly demonstrates the advantages of academic pathologists in arriving at the right diagnosis. Improved accuracy rates translate into improved treatment outcomes, and this renewal shows Yale’s strong dedication to the cause of delivering a high level of diagnostic expertise to the medical community.”
Founded in 2011 and commencing clinical services in 2012, Precipio established its own laboratory in New Haven, CT alongside its partner, Yale University. The Company began its focus in cancer where the problem of misdiagnosis carries grave consequences.
“For many years I have believed that the resources and expertise developed within world-class academic institutions have not been properly utilized to benefit patients outside the walls of the university,” said Professor Jon Morrow, MD, PhD, Chair of the Department of Pathology at Yale School of Medicine. “When the team at Precipio approached us with this novel idea, I saw an opportunity to expand our reach into the community setting, while helping patients and their physicians gain access to some of the brightest minds in the field. I am excited to continue building the partnership with Precipio and expand our service into other fields as well.”
About Precipio
Precipio is a diagnostic company leveraging the medical expertise of highly respected academic institutions by providing exceedingly accurate diagnostic capabilities to physicians and their patients, therefore reducing the frequency of misdiagnosis. By doing so, physicians can help ensure that optimal treatment programs are recommended, improving patient outcomes and quality of life. Recognizing that the incorporation of cutting edge technologies could be utilized to further aid the diagnostic process with our academic partners, Precipio entered into a definitive merger agreement with Transgenomic, Inc. (OTCQB:TBIO) in late 2016. Transgenomic’s Ice-Cold PCR (ICP), developed at the Dana Farber Cancer Center in Harvard University and licensed to Transgenomic, represents the first of several technologies that Precipio will add to its platform with the objective of further improving diagnostic accuracy for physicians and their patients. As Precipio continues to expand its platform of academic institutions, it will build its cadre of world-class experts, and grow an arsenal of intellectual property-based technologies to further solutions that eradicate the problem of misdiagnosis. For more information on the Company, please visit www.precipiodx.com .
Company Contact:
Ilan Danieli, CEO
pr@precipiodx.com
Investor Relations Contact:
Mike Cole
MZ North America
949-259-4988
mike.cole@mzgroup.us
LOL ! ...what a SCAM
http://ih.advfn.com/p.php?pid=nmona&article=74224339
New York, NY -- March 30, 2017 -- InvestorsHub NewsWire -- Wall Street Corner Report
Our 1000% ROI Cannabis Stock Portfolio Outlook Between Now and Cannabis 420 Celebration Based On VERY BULLISH Cross The Board Analyst Rating
MLCG -
Current: $0.0005
Potential By 420: $0.005
All four companies seem to be building toward the Texas 420 Celebration at the coming Southwest Cannabis Conference and Expo April 22-23. This is a big year in Texas with medical marijuana already passed and the first licenses to be issued in September.
Wall Street Corner Report also believes the current PPS of MLCG and PURA is ideal right now to support a BUY strategy benefiting from the inevitable news coming between now and the Cannabis Industry 420 Events next month.
Amended Statement of Beneficial Ownership (sc 13d/a)
04/11/2017
http://ih.advfn.com/p.php?pid=nmona&article=74319520
On April 7, 2017, the Reporting Persons entered into call option agreements with BV Advisory Partners, LLC and Kuzven Precipio Investor, LLC, which agreements are filed herewith as Exhibit 23 and Exhibit 24, respectively, and incorporated herein by reference (the “Call Option Agreements”) pursuant to which the Reporting Persons granted a call option to each party to purchase an aggregate of 7,900,000 shares of Company Common Stock from the Reporting Persons for $1.00 in the event that certain conditions set forth in the Call Option Agreements are satisfied relating to a proposed bridge financing transaction and prospective merger between New Haven Labs Inc., a wholly owned subsidiary of the Company, and Precipio Diagnostics, LLC (the “Merger”).
and dilution goes on...
...dead money
Just setup #biotrack system & veg room for #greenleaffarms. State certification coming! Slated to be the most advanced 30k sf grow! $MCIG
Twitter: @mcigs
Just setup #biotrack system & veg room for #greenleaffarms. State certification coming! Slated to be the most advanced 30k sf grow!$MCIG pic.twitter.com/FFkGxcz4Lv
— Bots, Inc. (@Bots_bz) March 31, 2017
...2 weeks later again
and again and again and again....
Vegas Green Rush Is On! New annoucment from Nevada State. All facilities must be operational by may 31st to fast track recreational license.
Twitter: @mcigs
Vegas Green Rush Is On!
— Bots, Inc. (@Bots_bz) March 28, 2017
New annoucment from Nevada State.
All facilities must be operational by may 31st to fast track recreational license.
Very Productive Week Of Meetings, Negotiations, & Inspections.
Twitter: @mcig
Very Productive Week Of Meetings, Negotiations, & Inspections.$MCIG #WINNING !!!
— Bots, Inc. (@Bots_bz) March 17, 2017
...wait a minute - one week later again